Cerebral Vein Thrombosis Clinical Trial
Official title:
Venous Sinus Thrombosis : Clinical Picture and Outcome
Verified date | January 2022 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Cerebral venous sinus thrombosis (cvst) is an underdiagnosed neurological condition with variable clinical presentations and variable risk factors CVST is often an underdiagnosed cause of acute or slowly progressive neurological deficit. With increasing awareness of the entity and easy accessibility to the non-invasive test like CT and MRI scans,CVST cases are now being diagnosed more frequently and it is now thought to occur more commonly than previously assumed.it is also probably true that this condition is more frequent in underdeveloped countries
Status | Not yet recruiting |
Enrollment | 50 |
Est. completion date | June 1, 2023 |
Est. primary completion date | April 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. All patients admitted to the neurology department and ER of an assuit university hospital with the diagnosis of venous sinus thrombosis 2. accepting to participate in the study 3. of both sex above 18 years and below 70 years Exclusion Criteria: - 1. any case evident to have neurological deficit due to cause other than venous sinus thrombosis 2. patients refused to participate in this study 3-patients with uncertainty about her imaging study |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | cerebral venous sinus thrombosis | Clinical presentations of cerebral venous sinus thrombosis | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04569279 -
Rivaroxaban vs. Warfarin in CVT Treatment
|
Phase 3 | |
Recruiting |
NCT03778502 -
DOAC in Unusual Site Venous Thrombosis
|
||
Completed |
NCT02585713 -
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
|
Phase 3 | |
Active, not recruiting |
NCT03329365 -
Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS
|
||
Active, not recruiting |
NCT03080883 -
Apixaban in Preventing Secondary Cancer Related Venous Thrombosis in Cancer Patients Who Have Completed Anticoagulation Therapy
|
Phase 3 | |
Recruiting |
NCT05021198 -
The Norwegian Cerebral Venous Thrombosis Study
|
||
Completed |
NCT05448248 -
Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)
|